GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » Operating Cash Flow per Share

Lifecore Biomedical (Lifecore Biomedical) Operating Cash Flow per Share : $-0.58 (TTM As of May. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical Operating Cash Flow per Share?

Lifecore Biomedical's operating cash flow per share for the three months ended in May. 2023 was $-0.01. Lifecore Biomedical's operating cash flow per share for the trailing twelve months (TTM) ended in May. 2023 was $-0.58.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Lifecore Biomedical's Operating Cash Flow per Share or its related term are showing as below:

LFCR' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -21.9   Med: 2.4   Max: 74.7
Current: 0.1

During the past 13 years, Lifecore Biomedical's highest 3-Year average Operating Cash Flow per Share Growth Rate was 74.70% per year. The lowest was -21.90% per year. And the median was 2.40% per year.

LFCR's 3-Year OCF Growth Rate is ranked worse than
61.59% of 807 companies
in the Drug Manufacturers industry
Industry Median: 8.2 vs LFCR: 0.10

Lifecore Biomedical Operating Cash Flow per Share Historical Data

The historical data trend for Lifecore Biomedical's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical Operating Cash Flow per Share Chart

Lifecore Biomedical Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 -0.58 0.56 -0.77 -0.58

Lifecore Biomedical Quarterly Data
Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.05 -0.10 -0.42 -0.01

Competitive Comparison of Lifecore Biomedical's Operating Cash Flow per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Price-to-Operating-Cash-Flow falls into.



Lifecore Biomedical Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Lifecore Biomedical's Operating Cash Flow per Share for the fiscal year that ended in May. 2023 is calculated as

Operating Cash Flow per Share (A: May. 2023 )=Cash Flow from Operations (A: May. 2023 )/Shares Outstanding (Diluted Average) (A: May. 2023 )
=-17.441/29.958
=-0.58

Lifecore Biomedical's Operating Cash Flow per Share for the quarter that ended in May. 2023 is calculated as

Operating Cash Flow per Share (Q: May. 2023 )=Cash Flow from Operations (Q: May. 2023 )/Shares Outstanding (Diluted Average) (Q: May. 2023 )
=-0.272/30.318
=-0.01

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in May. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lifecore Biomedical Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifecore Biomedical (Lifecore Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.
Executives
Raymond T. White director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper director 12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian director C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter director C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg officer: Chief Financial Officer C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall officer: Executive Vice President 3515 LYMAN BLVD., CHASKA MN 55318